1
|
Nelson MAM, Efird JT, Kew KA, Katunga LA, Monroe TB, Doorn JA, Beatty CN, Shi Q, Akhter SA, Alwair H, Robidoux J, Anderson EJ. Enhanced Catecholamine Flux and Impaired Carbonyl Metabolism Disrupt Cardiac Mitochondrial Oxidative Phosphorylation in Diabetes Patients. Antioxid Redox Signal 2021; 35:235-251. [PMID: 33066717 PMCID: PMC8262387 DOI: 10.1089/ars.2020.8122] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Aims: Catecholamine metabolism via monoamine oxidase (MAO) contributes to cardiac injury in models of ischemia and diabetes, but the pathogenic mechanisms involved are unclear. MAO deaminates norepinephrine (NE) and dopamine to produce H2O2 and highly reactive "catecholaldehydes," which may be toxic to mitochondria due to the localization of MAO to the outer mitochondrial membrane. We performed a comprehensive analysis of catecholamine metabolism and its impact on mitochondrial energetics in atrial myocardium obtained from patients with and without type 2 diabetes. Results: Content and maximal activity of MAO-A and MAO-B were higher in the myocardium of patients with diabetes and they were associated with body mass index. Metabolomic analysis of atrial tissue from these patients showed decreased catecholamine levels in the myocardium, supporting an increased flux through MAOs. Catecholaldehyde-modified protein adducts were more abundant in myocardial tissue extracts from patients with diabetes and were confirmed to be MAO dependent. NE treatment suppressed mitochondrial ATP production in permeabilized myofibers from patients with diabetes in an MAO-dependent manner. Aldehyde dehydrogenase (ALDH) activity was substantially decreased in atrial myocardium from these patients, and metabolomics confirmed lower levels of ALDH-catalyzed catecholamine metabolites. Proteomic analysis of catechol-modified proteins in isolated cardiac mitochondria from these patients identified >300 mitochondrial proteins to be potential targets of these unique carbonyls. Innovation and Conclusion: These findings illustrate a unique form of carbonyl toxicity driven by MAO-mediated metabolism of catecholamines, and they reveal pathogenic factors underlying cardiometabolic disease. Importantly, they suggest that pharmacotherapies targeting aldehyde stress and catecholamine metabolism in heart may be beneficial in patients with diabetes and cardiac disease. Antioxid. Redox Signal. 35, 235-251.
Collapse
Affiliation(s)
- Margaret-Ann M Nelson
- Department of Pharmacology & Toxicology, Brody School of Medicine, East Carolina University, Greenville, North Carolina, USA
| | - Jimmy T Efird
- Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, University of Newcastle, Newcastle, Australia
| | - Kimberly A Kew
- Department of Biochemistry and Molecular Biology, Brody School of Medicine, East Carolina University, Greenville, North Carolina, USA
| | - Lalage A Katunga
- Department of Pharmacology & Toxicology, Brody School of Medicine, East Carolina University, Greenville, North Carolina, USA
| | - T Blake Monroe
- Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa, USA
| | - Jonathan A Doorn
- Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa, USA
| | - Cherese N Beatty
- Department of Pharmacology & Toxicology, Brody School of Medicine, East Carolina University, Greenville, North Carolina, USA
| | - Qian Shi
- Division of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA
| | - Shahab A Akhter
- Department of Cardiovascular Sciences, Brody School of Medicine, East Carolina Heart Institute, Greenville, North Carolina, USA
| | - Hazaim Alwair
- Department of Cardiovascular Sciences, Brody School of Medicine, East Carolina Heart Institute, Greenville, North Carolina, USA
| | - Jacques Robidoux
- Department of Pharmacology & Toxicology, Brody School of Medicine, East Carolina University, Greenville, North Carolina, USA
| | - Ethan J Anderson
- Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa, USA.,Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, Iowa, USA
| |
Collapse
|
2
|
Potential vascular α1-adrenoceptor blocking properties of metformin in rat aorta and tail artery. Eur J Pharmacol 2019; 858:172498. [DOI: 10.1016/j.ejphar.2019.172498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Accepted: 06/21/2019] [Indexed: 11/18/2022]
|
4
|
Mori A, Ishikawa E, Amano T, Sakamoto K, Nakahara T. Anti-diabetic drug metformin dilates retinal blood vessels through activation of AMP-activated protein kinase in rats. Eur J Pharmacol 2017; 798:66-71. [PMID: 28087254 DOI: 10.1016/j.ejphar.2017.01.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2016] [Revised: 12/20/2016] [Accepted: 01/09/2017] [Indexed: 12/29/2022]
Abstract
The aim of this study was to examine whether metformin, a biguanide anti-hyperglycemic drug, dilates retinal blood vessels in rats. Ocular fundus images were captured with an original high-resolution digital fundus camera in vivo and diameters of retinal blood vessels were measured. Both systemic blood pressure and heart rate were continuously recorded. Metformin (0.01-0.3mg/kg/min) increased diameters of retinal blood vessels in a dose-dependent manner. This retinal vasodilator effect of metformin was abolished by compound C, an inhibitor of AMP-activated protein kinase (AMPK), and NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide (NO) synthase. Similar results were obtained with the AMPK activator 5-aminoimidazole-4-carboxamide-1-β-D-ribonucleoside (AICAR, 0.01-1mg/kg/min). Neither metformin nor AICAR exerted significant effect on mean blood pressure and heart rate. However, a significant pressor response to AICAR was observed upon inhibition of NO synthase. These results suggest that metformin dilates retinal blood vessels through activation of AMPK, and NO plays an important role in the retinal vasodilator response following AMPK activation.
Collapse
Affiliation(s)
- Asami Mori
- Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Eriko Ishikawa
- Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Tomoyo Amano
- Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Kenji Sakamoto
- Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Tsutomu Nakahara
- Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan.
| |
Collapse
|
5
|
Peuler JD, Phelps LE. Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents. J Smooth Muscle Res 2015; 51:22-36. [PMID: 26004378 PMCID: PMC5137313 DOI: 10.1540/jsmr.51.22] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Type 2 diabetic men commonly experience erectile dysfunction for which
phosphodiesterase-5 (PDE5) inhibitors like sildenafil (Viagra) are often recommended. By
preventing degradation of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle,
these inhibitors also enhance arterial vasorelaxant effects of nitric oxide donors (which
stimulate cGMP synthesis). In the present work, we confirmed this enhancing effect after
co-administration of sildenafil with nitroprusside to freshly-isolated rat tail arterial
tissues. However, in the same tissues we also observed that sildenafil does not enhance
but rather attenuates vasorelaxant effects of three commonly-used antidiabetic drugs, i.e.
the biguanide metformin and the thiazolidinediones pioglitazone and rosiglitazone. Indeed,
sildenafil completely blocked vasorelaxant effects of low concentrations of these drugs.
In addition, we found that this same novel anti-vasorelaxant interaction of sildenafil
with these agents was abolished by either 1) omitting extracellular glucose or 2)
inhibiting specific smooth muscle glycolytic pathways; pathways known to preferentially
utilize extracellular glucose to fuel certain adenosine triphosphate (ATP)-dependent ion
transporters: e.g. ATP-sensitive K channels, sarcoplasmic reticulum Ca-ATPase, plasma
membrane Ca-ATPase and Na/K-ATPase. Accordingly, we suspect that altered activity of one
or more of these ion transporters mediates the observed attenuating (anti-vasorelaxant)
interaction of sildenafil with the antidiabetic drugs. The present results are relevant
because hypertension is so common and difficult to control in Type 2 diabetes. The present
data suggest that sildenafil might interfere with the known antihypertensive potential of
metformin and the thiazolidinediones. However, they do not suggest that it will interact
with them to cause life-threatening episodes of severe hypotension, as can occur when it
is co-administered with nitrates.
Collapse
Affiliation(s)
- Jacob D Peuler
- Department of Pharmacology, Midwestern University, Downers Grove, IL, USA
| | | |
Collapse
|
6
|
McCarthy EA, Walker SP, McLachlan K, Boyle J, Permezel M. Metformin in obstetric and gynecologic practice: a review. Obstet Gynecol Surv 2004; 59:118-27. [PMID: 14752300 DOI: 10.1097/01.ogx.0000109224.52893.b8] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Metformin is a common treatment for women who have insulin resistance manifesting as type 2 diabetes or polycystic ovarian syndrome (PCOS). With an increasing number of these patients conceiving, it is expected that the use of metformin in and around the time of pregnancy will increase. This article reassesses the mechanisms, safety, and clinical experience of metformin use in obstetrics and gynecology. Metformin is an attractive therapeutic option because administration is simple, hypoglycemia rare, and weight loss promoted. There is a large volume of research supporting the use of metformin treatment in diabetes mellitus, androgenization, anovulation, infertility, and recurrent miscarriage. Although metformin is known to cross the placenta, there is, as yet, no evidence of teratogenicity. Metformin has an array of complex actions, accounting for the varied clinical roles, many of which are still to be fully evaluated. Much research is still needed.
Collapse
Affiliation(s)
- Elizabeth A McCarthy
- University of Melbourne, Department of Obstetrics and Gynaecology, Mercy Hospital for Women, East Melbourne, Australia.
| | | | | | | | | |
Collapse
|